LEXINGTON, Ky. (Oct. 21, 2016) — The University of Kentucky Board of Trustees today accepted the appointment of R. Kiplin Guy as the new dean of the UK College of Pharmacy. Guy is a renowned researcher who specializes in the development of drugs to combat pediatric diseases and previously served as chairman of the Department of Chemical Biology and Therapeutics at St. Jude Children's Research Hospital.
At St. Jude's, Guy created the Department of Chemical Biology and Therapeutics, where he held the Robert J. Ulrich Endowed Chair. He also has held secondary appointments as adjunct professor of pharmaceutical chemistry for the University of California San Francisco; adjunct professor of biochemistry for Vanderbilt University in Nashville; and adjunct professor of pharmaceutical sciences and pathology for the University of Tennessee in Knoxville.
Guy's research focus is chemical biology and preclinical drug discovery and development for neglected diseases, especially those that affect children. Much of his work has focused on pediatric cancers and malaria. In recent years, he has led the team that discovered and developed a new drug candidate for malaria that is currently in Phase 1 trials. The Chemical Biology and Therapeutics group, built and led by Guy, has collaboratively repurposed drugs for clinical trials for ependymoma, leukemias, medulloblastoma, and other pediatric cancers.
UK is the University for Kentucky. At UK, we are educating more students, treating more patients with complex illnesses and conducting more research and service than at any time in our 150-year history. To read more about the UK story and how you can support continued investment in your university and the Commonwealth, visit uky.edu/uk4ky. #uk4ky #seeblue
MEDIA CONTACT: Allison Perry, 859-323-2399, email@example.com